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Abstract
Background: Although multidrug-resistant tuberculosis (MDR-TB) is emerging as a significant threat to tuberculosis control
in high HIV prevalence countries such as South Africa, limited data is available on the burden of drug resistant tuberculosis
and any association with HIV in such settings. We conducted a community-based representative survey to assess the MDR-
TB burden in Khayelitsha, an urban township in South Africa with high HIV and TB prevalence.
Methodology/Principal Findings: A cross-sectional survey was conducted among adult clinic attendees suspected for
pulmonary tuberculosis in two large primary care clinics, together constituting 50% of the tuberculosis burden in
Khayelitsha. Drug susceptibility testing (DST) for isoniazid and rifampicin was conducted using a line probe assay on positive
sputum cultures, and with culture-based DST for first and second-line drugs. Between May and November 2008, culture
positive pulmonary tuberculosis was diagnosed in 271 new and 264 previously treated tuberculosis suspects (sample
enriched with previously treated cases). Among those with known HIV status, 55% and 71% were HIV infected respectively.
MDR-TB was diagnosed in 3.3% and 7.7% of new and previously treated cases. These figures equate to an estimated case
notification rate for MDR-TB of 51/100,000/year, with new cases constituting 55% of the estimated MDR-TB burden. HIV
infection was not significantly associated with rifampicin resistance in multivariate analyses.
Conclusions/Significance: There is an extremely high burden of MDR-TB in this setting, most likely representing ongoing
transmission. These data highlight the need to diagnose drug resistance among all TB cases, and for innovative models of
case detection and treatment for MDR-TB, in order to interrupt transmission and control this emerging epidemic.
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Introduction
There are an estimated 13,000 cases of multidrug-resistant
tuberculosis (MDR-TB) emerging in South Africa each year [1].
These estimates are primarily based on a national survey
performed in 2001, combined with routinely reported case
numbers, and thus many believe this to be an under-estimation
of the current situation. In addition, South Africa has a growing
epidemic of extensively drug-resistant tuberculosis (XDR-TB)
associated with high mortality among HIV infected individuals
[2]. The continued emergence of MDR- and XDR-TB poses a
significant threat not only to tuberculosis control but also to
progress made in the expanded provision of antiretroviral
treatment (ART) for HIV.
Drug-resistant tuberculosis (DR-TB) requires much longer and
more costly treatment regimens than drug-susceptible tuberculosis,
and in most high HIV prevalence settings, there is limited capacity
for diagnosis. Thus, in many settings, few patients are diagnosed
with DR-TB and even fewer receive adequate treatment. The
HIV epidemic has driven dramatic increases in tuberculosis case
notifications in southern Africa [3]. While expanding access to
ART is expected to ultimately reduce tuberculosis case notifica-
tions, it may also contribute to the large pool of individuals with
increased vulnerability to TB created by the HIV epidemic [4].
The convergence of these conditions: the high rate of tuberculosis
prevalence, a vulnerable population and the existence of
undiagnosed and untreated drug resistant tuberculosis create the
potential for dramatically increasing epidemics.
To date, there have been limited data available on the
prevalence of DR-TB in high HIV prevalence settings. Only 12
countries in the African region have conducted nationwide surveys
since 2000, with few disaggregating by HIV status [1]. While a
number of countries are planning national representative surveys,
such surveys aimed at deriving nationwide estimates of DR-TB
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resistance, particularly in settings with existing high rates of both
HIV and tuberculosis. There is an urgent need to quantify the
extent of the drug resistant tuberculosis epidemic in these settings
in order to advocate for and develop strategies for control. This
study aimed to assess the burden of tuberculosis drug resistance in
a peri-urban setting in Khayelitsha Township outside Cape Town,
South Africa.
Methods
Study setting
Khayelitsha is a high population density township situated
30 km from Cape Town with a population estimated at more than
500,000. Poverty and unemployment are high and the majority
live in informal housing. In 2006, the prevalence of HIV among
antenatal clinic attendees was 33% and close to 6,000 tuberculosis
cases were notified in 2008, giving an estimated case notification
rate of 1158/100,000/year (based on an estimated population of
500,000) [5,6]. In response to increasing numbers of DR-TB cases
seen in Khayelitsha clinics and poor patient outcomes, a pilot
project to provide community-based care and treatment for DR-
TB was initiated in 2007 [7]. The pilot project is implemented by
Me ´decins Sans Frontie `res (MSF) in collaboration with the City of
Cape Town and the Provincial Government of the Western Cape.
Survey design
A cross-sectional survey among clinic attendees suspected for
pulmonary tuberculosis was conducted in two large primary care
clinics in Khayelitsha between May and November 2008. These
clinics combined account for 50% of the TB case burden in
Khayelitsha. Clinic attendees, aged 18 years and over, not
currently receiving TB treatment and in whom tuberculosis was
suspected clinically, were eligible to participate. The study was
explained by clinic staff and written informed consent was
obtained from each participant. The study was approved by the
University of Cape Town Ethical Review Committee and by both
the City of Cape Town and the Western Cape Province Health
Department.
The desired sample size was determined separately for new and
previously treated culture positive TB cases. Previous tuberculosis
treatment was defined as 1 month or more of anti-tuberculosis
treatment. Based on estimated proportions of MDR-TB of 2% and
4% respectively in South Africa [8], minimum sample sizes were
121 and 236 respectively (precision 2.5% and 5% alpha level). For
logistical reasons and allowing for missing data, a target of 250 in
each category was sought.
Drug susceptibility testing
Two sputum samples were collected one hour apart and were
transported the same day to the National Health Laboratory
Service (NHLS) TB laboratory in Cape Town as per routine
practice. Fluorescence sputum smear microscopy was performed
on both sputum specimens in accordance with guidelines from the
International Union Against Tuberculosis and Lung Disease
(IUATLD) [9]. One specimen was cultured using the BACTEC
MGIT 960 system (BD Diagnostics Systems, Sparks, MD). Positive
cultures were confirmed as Mycobacterium tuberculosis complex using
Ziehl-Neelsen staining and p- nitrobenzoic acid testing [10].
Resistance to rifampicin and isoniazid was determined on
positive cultures using a rapid line probe assay (LPA) (Hain
GenoType MTBDRplus) as previously trialled in this laboratory
[11]. All subcultures were later transported to the NHLS
laboratory in Johannesburg for conventional culture-based drug
susceptibility testing to rifampicin, isoniazid, ethambutol, pyrazin-
amide, streptomycin, ofloxacin, ethionamide and the second-line
injectable agents (amikacin, kanamycin and capreomycin) also
using the BACTEC MGIT 960 system. Two concentrations of
isoniazid were tested, 0.1 and 0.4 mg/ml, to assess high and low
level isoniazid resistance [12]. For rifampicin and isoniazid, drug
resistance was defined as resistance shown on either the rapid LPA
or the conventional culture based susceptibility test. For isoniazid,
low level resistance was defined as resistant. Multidrug resistant
tuberculosis (MDR-TB) is defined as resistance to both isoniazid
and rifampicin and extensively drug resistant tuberculosis (XDR-
TB) is defined as MDR-TB with additional resistance to a
fluoroquinolone and a second-line injectable agent.
Data collection and analysis
Data on previous TB treatment, demographics, HIV status and
antiretroviral treatment at the time of TB diagnosis were recorded
routinely during the clinical assessment by a primary care nurse.
Data on previous TB treatment was additionally verified among
patients starting treatment through a medical record review. All
data were entered on a database using Excel (Microsoft Office
2003). Data analysis, including multivariate logistic regression
models, was conducted with SPSS (Release 17.0.0, 2008).
To investigate factors potentially associated with rifampicin
resistance, both univariate and multivariate logistic regression
analyses were conducted. Previous TB treatment was classified as
either: new (not previously treated), the most recent TB treatment
episode in 2007/08 (the survey was conducted between May and
November 2008) or the most recent treatment episode prior to
2007. Factors significant or approaching significance (p=0.05) on
univariate analysis were entered into the multivariate logistic
regression models. Factors were coded as categorical variables with
missing data included as a category. All factors were entered as a
block into multivariate logistic regression models and goodness of
fit was assessed with the Hosmer and Lemeshow statistic [13].
The MDR-TB burden in Khayelitsha was estimated by
applying the proportions of MDR-TB found through the survey
to the case notification data for the whole of Khayelitsha in 2008
[6]. Estimated MDR-TB incidence was then calculated using an
estimated population for Khayelitsha of 500,000. An approxima-
tion of MDR-TB transmission was made based on the assumptions
that DR-TB among new cases represents transmission rather than
acquired drug resistance and that the same level of primary
transmission is likely to occur among previously treated TB cases,
given extensive reinfection in endemic settings.
Results
Culture positive tuberculosis
During the study period, 1,842 (96%) of the 1,928 eligible clinic
attendees suspected for pulmonary tuberculosis seen in the two
clinics were recruited to the survey (Figure 1). Recruitment of
participants not previously treated for tuberculosis ended in
August 2008 as the desired sample size was estimated to have been
reached. Recruitment of previously treated participants continued
until November 2008, hence the overall combined sample does
not reflect the relative proportions of new and previously treated
TB suspects seen in the clinics.
In TB suspects for whom valid culture results were obtained
(including valid positive and negative cultures), culture positive
tuberculosis was diagnosed in 271/732 (37%) cases among those
not previously treated and 264/843 (31%) cases among those with
more than one month of previous tuberculosis treatment (Figure 1).
The most common reasons for not obtaining a valid culture were
MDR-TB in Khayelitsha
PLoS ONE | www.plosone.org 2 November 2010 | Volume 5 | Issue 11 | e13901contamination, non-tuberculosis mycobacteria and lost or leaked
sputum samples. After investigation, 17 culture positive cases were
excluded as the previous tuberculosis treatment status could not be
determined (Figure 1).
HIV status was known for 88% of new and 90% of previously
treated cases (Table 1). The most common reason for unknown
HIV status was refusal to be tested. Among new TB cases with
known HIV status, 55% were HIV infected, while 71% of
previously treated cases were HIV positive (p=0.001).
First-line anti-tuberculosis resistance
Valid LPA results were obtained for 267 (98.5%) of the 271 new
TB cases and 259 (98.1%) of the 264 previously treated TB cases.
Valid culture-based DST results were available for 237 (87.5%)
and 221 (83.7%) of new and previously treated cases respectively
(Table 2). Overall, resistance data (either LPA and/or culture
DST) was available for 269 new and 261 previously treated TB
cases (Table 2). Contamination of subsequent subcultures was the
most common reason for missing culture DST results.
The line probe assay identified more rifampicin resistant cases
than did culture-based DST, while more isoniazid resistance was
identified through culture-based DST (Table 2). Overall, using
both the LPA and culture-based DST results, 3.3% (9/269) and
7.7% (20/261) of new and previously treated cases were found to
be infected with MDR-TB strains, with 5.2% (14/269) and 11.1%
(29/261) infected with rifampicin resistant TB respectively
(Table 2). Poly-resistance, most commonly isoniazid resistance
combined with other first-line resistance apart from rifampicin was
also frequently identified.
Table 3 compares the resistance profile from culture-based DST
with that from the LPA for the 29 cases defined as MDR-TB. Of
the 26 MDR-TB cases identified using the LPA, 7 were not able to
be assessed with conventional culture-based DST, while 2 cases
were defined as MDR-TB based on rifampicin resistance from the
LPA and isoniazid resistance from conventional culture-based
DST. A further MDR-TB case was susceptible using the LPA.
Second-line anti-tuberculosis resistance
Among the 22 MDR-TB cases with culture-based DST
available, 9 (41%) were found to have additional second-line
resistance, including 7 (32%) with resistance to a fluoroquinolone
or a second-line injectable agent or both (Table 3). Second-line
resistance was also observed among strains with no first-line
resistance and with mono- and poly-resistance to first-line drugs,
most commonly resistance to ethionamide and capreomycin
(Table 4).
Estimating the burden of tuberculosis drug resistance in
Khayelitsha
In 2008, 5,791 cases of pulmonary tuberculosis were reported
from primary care clinics in Khayelitsha. When the percentages of
MDR-TB are applied to these case notification figures, 257 MDR-
TB cases would have been diagnosed if all TB cases were tested:
Figure 1. Participant recruitment and culture-positive tuberculosis diagnosed among TB suspects. New TB suspects were recruited from
May through August, while previously treated suspects were recruited May through November, 2008. * Valid culture results include negative and
positive cultures and exclude contaminated cultures, those found to be non-tuberculous mycobacteria or those with no growth.
doi:10.1371/journal.pone.0013901.g001
Table 1. HIV status, sex and age among new and previously treated culture positive TB cases (IQR= interquartile range).
New TB Previously treated TB
Total 271 264
HIV negative
HIV positive
HIV status unknown
106
132 (55% of known HIV status)
33 (12%)
70
168 (71% of known HIV status)
26 (10%)
Male
Female
155
116 (43%)
167
96 (36%)
Median age (IQR)
Age 18–25
Age 26–35
Age 36+
32 (13)
58 (21%)
118 (44%)
95 (35%)
36 (13)
34 (13%)
102 (39%)
128 (48%)
doi:10.1371/journal.pone.0013901.t001
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new and previously treated culture-positive TB cases.
New TB cases Previously treated TB cases
Total (positive culture) 271 264
LPA results available 267 259
Susceptible 244 (91%) 223 (86%)
H-mono 11 (4.1%) 7 (2.7%)
R-mono 4 (1.5%) 11 (4.2%)
MDR-TB 8 (3.0%) 18 (6.9%)
Any Rifampicin resistance 12 (4.5%) 29 (11.2%)
Any Isoniazid resistance 19 (7.1%) 25 (9.7%)
Culture-based DST available 237 221
Susceptible to first-line 186 (79%) 167 (76%)
First-line mono-resistance 35 (14.8%) 38 (17.2%)
H-mono 8 (3.4%) 15 (6.8%)
R-mono 2 (0.8%) 2 (0.9%)
First-line poly-resistance 9 (3.8%) 5 (2.3%)
MDR-TB Total 7 (3.0%) 11 (5.0%)
MDR-TB with second line resistance 3 (1.3%) 5 (2.3%)
XDR-TB 1 (0.4%) 1 (0.5%)
Any Rifampicin resistance 9 (3.8%) 13 (5.9%)
Any Isoniazid resistance 22 (9.3%) 31 (14.0%)
Either LPA and culture DST 269 261
MDR-TB 9 (3.3%) 20 (7.7%)
Any Rifampicin resistance 14 (5.2%) 29 (11.1%)
Any Isoniazid resistance 28 (10.4%) 41 (15.7%)
doi:10.1371/journal.pone.0013901.t002
Table 3. Resistance profile (first and second-line) for all MDR-TB cases (abbreviations: H= isoniazid, R= rifampicin, E=
ethambutol, S= streptomycin, Z= pyrazinamide, Eto = ethionamide, Amk = amikacin, Km = kanamycin, Cm = capreomycin,
Ofx = ofloxacin).
Resistance profile – culture-based DST LPA MDR-TB LPA Susc LPA R-mono
no culture DST available 7
Susceptible 1
H 11
HR 2
HRE 11
HRS 1
HREZ 3
HRSZ 2
HREZ Eto 1
HRESZ Eto 1
HZ Amk 1
HRS Km 1
HRESZ Ofx 1
HRESZ Eto Km Amk Cm 1
HRESZ Eto Ofx 1
HRESZ Eto Ofx Km Amk Cm 2
Total 26 1 2
doi:10.1371/journal.pone.0013901.t003
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(55%) would have been diagnosed among new, not previously
treated TB suspects. These figures equate to an estimated
notification rate of 51/100,000/year for MDR-TB, if all TB
cases were to be tested. If MDR-TB among new cases represents
direct transmission, then at least 141 (55%) of the estimated 257
MDR-TB cases are due to transmission. This proportion rises to
81% if we assume that a similar level of transmission occurs among
the previously treated cases (Figure 2).
Association between HIV infection, other factors and
rifampicin resistant tuberculosis
Given the significant burden of rifampicin resistance not defined
as MDR-TB, associations with HIV infection and other factors
were assessed with rifampicin resistance. Among HIV infected new
cases, 5.3% (7/131) were rifampicin resistant, compared to 3.8%
(4/105) among HIV negative new cases. For HIV infected
previously treated cases, 13.9% (23/165) were rifampicin resistant
compared to 5.7% (4/70) among HIV negative cases. For the total
combined sample, there was a significant association between HIV
infection and rifampicin resistance on univariate analysis, but this
did not reach significance in the multivariate analysis (OR=2.26,
95% CI 0.91–5.61); a recent TB treatment episode and female sex
were significant predictors (Table 5). As previous tuberculosis
treatment is suggestive of drug resistance acquired under selective
pressure of previous treatment, a separate multivariate model was
constructed among previously treated TB cases only (Table 5).
Similarly, the association with HIV infection did not reach
significance (OR=3.10, 95% CI 0.85–11.33) A recent TB
treatment episode was the only significant factor associated with
rifampicin resistance in this model, with female sex no longer
significant. To further investigate associations between previous
TB treatment, HIV infection and rifampicin resistance, a third
multivariate model was constructed among HIV positive cases
only (Table 5). Only a recent TB treatment episode was predictive
of rifampicin resistance in this model.
Table 4. Second-line resistance among strains not defined as
MDR-TB.
Resistance profile Number
R Eto 1
H Eto 3
HS Eto 2
HZ Amk 1
Eto 7
Cm 6
Amk Cm Eto 1
Cm Ofx 1
doi:10.1371/journal.pone.0013901.t004
Figure 2. Estimating the burden of rifampicin resistant tuberculosis in Khayelitsha.
doi:10.1371/journal.pone.0013901.g002
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Eastern Europe and the former Soviet Union have been
described as global ‘‘hot spots’’ for tuberculosis drug resistance
[14]. This has primarily been based on assessments of the proportion
of all TB cases suffering from drug resistant disease. However a
more accurate reflection of the burden imposed by MDR-TB and
the threat of increasing spread can be given through assessing
population based incidence rather than proportions [15]. Using this
approach, South Africa has an estimated population incidence of
MDR-TB similar to that in the Russian Federation; 26/100,000/
year and 27/100,000/year respectively [1].
The data presented here show that in Khayelitsha, a densely
populated urban township in South Africa, the estimated burden
of MDR-TB is extremely high, at 51/100,000/year based on
notified TB cases, with incidence likely to be considerably higher
taking into account incomplete tuberculosis case detection in the
community. A large proportion of MDR-TB cases have pre-
existing second-line tuberculosis resistance and indeed XDR-TB
in the absence of extensive previous second-line treatment (data
not shown). These data suggest a burden of MDR-TB more than
twice that previously estimated for South Africa. Given the high
population density, poverty, high HIV and TB prevalence in
Khayelitsha, these data are unlikely to be representative
Table 5. Univariate and multivariate analyses to assess associations with rifampicin resistance among all, previously treated, and
HIV positive culture positive TB cases.
Univariate Multivariate
Factor Categories
Rifampicin
resistant TB (%) OR 95% CI P value OR 95% CI P value
Model includes all TB cases
Previous TB
treatment
New (ref)
Prev. TB 2006 or before
Prev. TB 2007/08
Missing
14 (5.2%)
10 (6.5%)
15 (18.3%)
4 (15.4%)
1.27
4.08
3.31
0.55–2.94
1.88–8.86
1.00–10.92
0.57
,0.0001
0.049
1.40
4.42
4.23
0.59–3.32
1.97–9.93
1.22–14.59
0.45
,0.0001
0.023
HIV status Negative (ref)
Positive
Missing
7( 4 . 0 % )
30 (10.1%)
6 (10.2%)
2.71
2.71
1.16–6.30
0.88–8.44
0.021
0.084
2.26
2.89
0.91–5.61
0.90–9.33
0.079
0.075
Sex Male (ref)
Female
18 (5.6%)
25 (12.0%) 2.30 1.22–4.33 0.010 2.03 1.01–4.06 0.047
Age 26+ (ref)
18–25
31 (7.1%)
12 (13.2%)
2.00
0.98–4.06 0.055 2.16 1.0–4.70 0.051
Hosmer and Lemeshow p=0.166
Model includes only previously treated TB cases
Most recent TB
episode
2006 or bef (ref)
2007/08
Missing
10 (6.5%)
15 (18.3%)
4 (15.4%)
3.20
2.60
1.3–7.5
0.75–9.02
0.007
0.13
3.42
3.02
1.43–8.15
0.85–10.80
0.006
0.089
HIV status Negative (ref)
Positive
Missing
3( 4 . 3 % )
23 (13.9%)
3 (11.1%)
3.62
2.91
1.1–12.5
0.55–15.46
0.04
0.21
3.10
3.17
0.85–11.33
0.57–17.5
0.087
0.19
Sex Male (ref)
Female
13 (7.8%)
16 (17.0%) 2.41 1.1–5.3 0.03 1.97 0.85–4.56 0.11
Age 26+ (ref)
18–25
22 (8.7%)
6 (18.2%) 1.98 0.74–5.30 0.17
Hosmer and Lemeshow p=0.273
Model includes only HIV positive TB cases
Previous TB
treatment
New (ref)
Prev. TB 2006 or before
Prev. TB 2007/08
Missing
7( 5 . 3 % )
7( 7 . 1 % )
14 (26.9%)
2 (13.3%)
1.36
6.53
2.73
0.46–4.02
2.46–17.34
0.51–14.51
0.58
,0.0001
0.24
1.67
7.27
4.26
0.53–5.23
2.61–20.25
0.74–24.37
0.38
,0.0001
0.103
ART at TB
diagnosis
No ART (ref)
On ART at diag
Missing
18 (8.7%)
9 (17.3%)
3( 7 . 9 % )
2.19
0.89
0.92–5.20
0.25–3.20
0.077
0.87
1.59
0.88
0.62–4.08
0.23–3.33
0.34
0.85
Sex Male (ref)
Female
10 (6.9%)
20 (13.2%) 2.05 0.92–4.54 0.078 1.90 0.81–4.50 0.14
Age 26+ (ref)
18–25
23 (8.9%)
7 (18.4%) 2.31 0.92–5.82 0.077 2.18 0.75–6.33 0.15
CD4 at TB
diagnosis
CD4 .100 (ref)
CD4 ,100
CD4 missing
11 (8.5%)
12 (15.8%)
7( 7 . 8 % )
2.03
0.91
0.84–4.86
0.34–2.45
0.11
0.86
Hosmer and Lemeshow p=0.991
doi:10.1371/journal.pone.0013901.t005
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reflective of the large proportion of South Africans who are most
at risk for tuberculosis. Urban and peri-urban townships like
Khayelitsha therefore should be the focus of particular attention
for both surveillance and epidemic control.
Currently available diagnostics for tuberculosis drug resis-
tance rely on culture and are therefore slow, cumbersome and
commonly only available through centralised laboratories. As a
result, DST is only selectively available if at all and even in
South Africa is only available for previously treated TB cases.
The data from Khayelitsha suggest that a large proportion of
MDR-TB cases occur in new TB suspects, who are not
routinely tested for drug resistance. These patients are
therefore likely to receive ineffective first-line anti-tuberculosis
treatment resulting in likely amplification of resistance, poor
treatment outcomes including increased mortality, and not
least fuelling increasing transmission through remaining
infectious and inadequately treated in the community. If
DST is only accessible for those failing treatment, a large
proportion of cases will be missed due to the high risk of death
among HIV positive patients with untreated DR-TB [2]. Early
diagnosis and improved case detection, through increasing
access to DST, either with culture or newer diagnostics such as
the line probe assays, is therefore fundamental to both
identifying the scale of this epidemic and to developing
strategies for control, in addition to reducing mortality.
The extent of MDR-TB among new, previously untreated TB
c a s e si nt h i ss u r v e ys u g g e s t st h a ta tl e a s th a l fo fa l lM D R - T Bi s
due to ongoing primary transmission in Khayelitsha. Transmis-
sion may be even higher; up to 80% of cases may be
transmitted, as it cannot be assumed that MDR-TB among
previously treated cases is always due to resistance amplification.
W h i l et h i si sag r o s sa p p r o x i m a t i o no ft r a n s m i s s i o n ,c l e a r l y
transmission remains a substantial cause of incident MDR-TB
c a s e si nt h i ss e t t i n g .
Tuberculosis drug resistance has traditionally been blamed on
poor TB control programmes and poor patient compliance with
treatment. However, HIV infection has also been suggested to
contribute to both an increased risk of acquiring resistance and
to the risk of direct infection with DR-TB. Acquired rifamycin
resistance has been demonstrated among HIV positive TB
patients in well controlled clinical trials and other studies [16–
18]. Contributing factors in these studies include low CD4
levels, co-administration of ART, extra-pulmonary TB and
treatment for co-morbidities. Drug malabsorption has been
demonstrated among HIV positive patients receiving tubercu-
losis drugs [19,20], but there is limited data among those
receiving concomitan tA R T .G i v e nt h a ti nh i g hT Bp r e v a l e n c e
areas, HIV positive individuals, even those receiving ART, are
likely to repeatedly develop active tuberculosis and receive
treatment [21], the development of DR-TB, independent of
poor treatment adherence and other programme factors can be
hypothesised.
HIV infection was not significantly associated with rifampi-
cin resistant TB in multivariate analyses, either overall or
among previously treated TB cases in this large community
based representative survey. Rather, consistent significant
associations were found between recent TB treatment and
rifampicin resistance. These data suggest that any observed
associations between HIV infection and DR-TB may be
mediated through the propensity for HIV infected individuals
to be repeatedly treated for TB and that HIV is not an
independent risk factor for infection and development of active
DR-TB disease. However, without prospective data and
molecular genotyping of strains from subsequent TB episodes,
it is not possible to differentiate the extent of acquisition of
resistance during TB treatment, and the impact of HIV
infection and concomitant ART on resistance acquisition, from
reinfection with a DR-TB strain. It may be that HIV infect-
ed individuals who have been treated for TB previously are
more exposed to DR-TB in nosocomial settings. Indeed,
nosocomial transmission is suggested to be a significant cause
of MDR- and XDR-TB transmission in Msinga district,
KwaZulu Natal, South Africa [22], while previous hospital-
isation was also an independent predictor for MDR-TB among
previously treated TB cases in the South African national
prevalence survey [8].
This survey is subject to the usual limitations in survey design
and data collection. While restricted to two primary care clinics in
Khayelitsha, these two clinics were responsible for diagnosing and
treating approximately 50% of TB cases in Khayelitsha in 2008.
Nonetheless, if nosocomial transmission is a significant factor
driving DR-TB transmission, the risk of DR-TB infection through
a larger clinic may be greater than that in the smaller primary care
clinics in Khayelitsha. While previous tuberculosis treatment was
verified through medical record review when possible, there is
likely to be a tendency for patients to not report previous treatment
in order to avoid receiving daily streptomycin injections and the
longer treatment course. While such a bias could lower our
estimate of overall MDR-TB prevalence, the data still suggest a
substantial number of MDR-TB cases would be diagnosed if all
TB cases were to be tested.
The Khayelitsha tuberculosis treatment programme reports
reasonable treatment outcomes for 2008; currently treatment
success stands at 82% for new TB cases and 50% for previously
treated cases [6]. However this is a relatively recent improve-
ment, with outcomes prior to 2003 significantly lower than this,
including substantial rates of treatment interruption and
default. Such conditions are likely to have contributed to the
initial development of acquired resistance among patients
receiving poor tuberculosis treatment [23]. However, the data
presented here suggest that while acquired resistance may
remain important, the great majority of MDR-TB is now due to
direct transmission of already resistant tuberculosis strains. The
overall lack of association with HIV infection is therefore
unsurprising.
Although HIV infection, along with previous sub-optimal
tuberculosis treatment programmes, may have contributed to the
initial emergence of tuberculosis drug resistance, the high
community HIV prevalence in Khayelitsha does not appear to
be a significant factor selectively driving DR-TB transmission in this
setting. Rather high HIV prevalence is driving transmission of
both drug susceptible and drug resistant tuberculosis. High rates of
transmission of drug resistant tuberculosis highlight the need for
improved infection control measures, both in health care facilities
and at community level. Based on the large burden of DR-TB in
this setting and given that it is likely that the epidemic is being
driven by transmission, innovative models of care aiming to
diagnose and treat as many DR-TB cases as possible and as early
as possible will be required to interrupt transmission. Such models
will by necessity require rapid DR-TB diagnostics as close to point
of care as possible, and for all TB suspects, along with
decentralised treatment of patients. It is unlikely that any
centralised system will be able to cope with the large numbers of
patients requiring treatment or to hold them on treatment for the
full time required. Existing tuberculosis treatment services will
need to be utilised and strengthened in order to expand access to
diagnosis and treatment for drug resistant TB.
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